All In Biotech

Drug Trial Radar · NCT00337779

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind Study to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to That of Glatiramer Acetate Injection 20 mg/ml Administered Once Daily by Subcutaneous Injection in Subjects With Relapsing Remitting (R-R) Multiple Sclerosis (MS)

Last checked: Nov 20, 2026Latest source record: Oct 10, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,155 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,155

Actual

Start

Aug 2006

Primary completion

Oct 2008

Study completion Oct 2008

Sponsor

Sponsor type
Industry
First posted
Jun 16, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Teva is developing a 40 mg/ml GA Injection, administered once daily under the skin, for the treatment of R-R MS. The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the treatment of R-R MS. GA is an immunomodulating drug that has anti inflammatory and neuroprotective properties. The study treatment duration is 12 months.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

  • Glatiramer Acetate (GA) 40 mgDrug

    Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months

  • glatiramer acetate 20 mgDrug

    Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Rate of Confirmed Relapses During the Double-blind Phase (12 Months).Time frame: 12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.